CLINICAL_TRIALS
trial_result
· 2017-03-01
Clinical Trial Update: Decitabine for High-Risk Sickle Cell Disease [Phase 2]
Summary
This update reports results from a Phase 2 clinical trial of decitabine for high-risk sickle cell disease, with results posted in 2017.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Neutropenia, Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-03-01